导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -9.37% | 3708/4773 |
| 近一周 | -1.95% | 949/5462 |
| 近一月 | -4.01% | 2139/5421 |
| 近一季 | -6.33% | 2051/5209 |
| 近半年 | -14.16% | 3892/4920 |
| 近一年 | -8.38% | 3260/4366 |
| 近两年 | 38.57% | 1959/2954 |
| 近三年 | -2.52% | 1965/2253 |
| 成立以来 | -41.40% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-2.70% 2870/4961 |
1.48% 3017/5312 |
- - |
- - |
| 2025 | 16.11% 2486/4813 |
3.35% 1107/3635 |
-1.01% 3091/4076 |
16.77% 2605/4524 |
-2.80% 3210/4813 |
| 2024 | 1.49% 2006/3463 |
-5.52% 1920/2808 |
-9.21% 2332/3014 |
16.09% 1539/3129 |
1.92% 1005/3463 |
| 2023 | -11.30% 1390/2656 |
14.12% 249/2280 |
-7.76% 1903/2385 |
-7.87% 1634/2515 |
-8.54% 2300/2655 |
| 2022 | -24.36% 1210/2207 |
-19.80% 1493/1919 |
2.49% 1296/2016 |
-13.17% 852/2113 |
5.99% 402/2208 |
| 2021 | -3.97% 935/1822 |
-2.33% 620/1255 |
9.38% 553/1330 |
-9.22% 1169/1466 |
-0.99% 1293/1822 |
| 2020 | 7.50% 865/1250 |
-2.65% 270/1028 |
12.69% 676/1067 |
1.47% 1021/1164 |
-3.43% 1129/1184 |
| 2019 | 25.93% 589/1092 |
30.19% 257/739 |
-8.11% 576/788 |
0.62% 501/850 |
4.62% 793/918 |
| 2018 | -32.58% 535/834 |
- - |
-15.21% 515/631 |
-12.35% 611/660 |
-9.40% 144/682 |
| 2017 | 1.65% 449/714 |
- - |
- - |
- - |
- - |
| 2016 | -19.76% 436/605 |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 东海社会安全 VS. 长安沪深300非周期A(740101) |